2 unknown, 1 recruiting. 2 Phase 1, 2 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 1, Unknown 1 |
| Phase 2 | 2 | Recruiting 1, Unknown 1 |
| Not applicable | 1 | Unknown 1 |
Follow Smart Immune SAS: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT With Post-transplant Cyclophosphamide Allogeneic T cell progenitors, cultured ex-vivo - Hematological Malignancies | Phase 1 / Phase 2 | Unknown | Smart Immune SAS | 40 | 2023-06-06 | 2023-09-25 |
| Development of a Cell Culture Process for the Production of Human T-lymphocyte Precursors Collection of mobilized hematopoietic stem cells (apheresis products) from healthy volunteers - Healthy Volunteers | Not applicable | Unknown | Smart Immune SAS | 14 | 2022-04-26 | 2023-11-21 |
| Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT Allogeneic T cell progenitors, cultured ex-vivo - Hematological Malignancies | Phase 1 / Phase 2 | Recruiting | Smart Immune SAS | 36 | 2022-03-31 | 2023-03-06 |
Hematologic Neoplasms (2) · Leukemia, Myeloid, Acute (1) · Multiple Sulfatase Deficiency Disease (1)
France (2) · United States (1)